-
公开(公告)号:US20190292546A1
公开(公告)日:2019-09-26
申请号:US16348775
申请日:2017-11-10
申请人: Centre Léon-Bérard , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , Centre national de la recherche scientifique , Université Claude Bernard Lyon 1 , HOSPICES CIVILS DE LYON
IPC分类号: C12N15/117 , C12N5/09 , A61K31/337 , A61N5/10
摘要: The present invention relates to a TLR3 agonist for use for inducing apoptosis in senescent cancer cells, in particular to a TLR3 agonist for use as a medicament for inducing apoptosis in senescent cancer cells. In particular, it relates to a TLR3 agonist for use for the treatment of cancer, optionally in combination with a chemotherapeutic agent or with radiotherapy. It further relates to a pharmaceutical composition comprising a TLR3 agonist and a chemotherapeutic agent.
-
公开(公告)号:US20210292328A1
公开(公告)日:2021-09-23
申请号:US16334513
申请日:2017-09-20
申请人: CENTRE LEON BERARD , HOSPICES CIVILS DE LYON , UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
IPC分类号: C07D487/04 , C07D235/18 , C07D401/12 , C07D403/12 , C07D401/04 , C07D413/12 , C07D405/12 , C07D403/04 , C07D401/14 , A61K45/06 , C07D417/12
摘要: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
-
公开(公告)号:US20220348587A1
公开(公告)日:2022-11-03
申请号:US17831592
申请日:2022-06-03
申请人: CENTRE LEON BERARD , HOSPICES CIVILS DE LYON , UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHESCIENTIFIQUE (CNRS) , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
IPC分类号: C07D487/04 , A61K45/06 , C07D235/18 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
-
-